This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Journal Club
Clinical Paper of the Month - Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial
Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial

Publishing date: April 2021

Author(s): Thomas W Samuelson (1), Inder Paul Singh (2), Blake K Williamson (3), Heather Falvey (4), Won Chan Lee (5), Dawn Odom (6), David McSorley (6), L Jay Katz (4)

1 Minnesota Eye Consultants, Minneapolis, Minnesota, USA.
2 Eye Centers of Racine and Kenosha, Wisconsin, USA.
3 Williamson Eye Center, Baton Rouge, LA, USA.
4 Glaukos, San Clemente, CA, USA.
5 Econforte Consulting LLC, San Francisco, CA, USA.
6 RTI Health Solutions, Research Triangle Park, NC, USA.

OBJECTIVE: To assess QOL as measured by patient-reported outcomes (PRO) within the iStent inject pivotal trial.

DESIGN: Randomized controlled trial analysis of secondary outcomes.

METHODS: The Vision Function Questionnaire (VFQ-25) and Ocular Surface Disease Index (OSDI©) questionnaire were administered at baseline, months 1, 6, 12, and 24. PRO responders were defined as patients reaching improvement based on minimally important differences.

RESULTS: 505 patients were randomized (N = 386 iStent inject, N = 119 surgery alone). The iStent inject group exhibited a greater percentage of PRO responders across all follow-up visits over 24 months, averaging 58.0% vs. 45.8%; P < .05 for VFQ-25 composite scores and 56.7% vs. 48.9%; P < .05 for OSDI composite scores. Odds of being a responder in the iStent inject group was 60% (P < .05) higher for the VFQ-25 and 32% (P > .05) higher for the ODSI. Driving (49.0% vs. 28.8%; P < .05), ocular pain (59.3% vs. 47.2%; P < .05) and general vision (71.8% vs. 60.0%; P < .05), were the VFQ-25 subscales responsible for differences between treatment groups. At month 24, 76.5% of VFQ-25 responders and 62.5% of non-responders were medication free regardless of treatment group (P < .05).

CONCLUSIONS: Exploratory analysis suggests that by reducing medication dependence, implantation with the micro-scale iStent inject device with cataract surgery may improve QOL vs. cataract surgery alone over 24 months with improvements influenced by ocular symptoms and vision related activities.

Copyright © 2021. Published by Elsevier Inc.
Am J Ophthalmol. 2021 Mar 15;S0002-9394(21)00120-3. doi: 10.1016/j.ajo.2021.03.007. Online ahead of print.

PMID: 33737036

Keywords: OSDI; PRO; QOL; VFQ-25; iStent inject; open angle glaucoma; patient-reported outcomes; vision-related quality of life

Clinical Paper of the Month manager: Anthony Khawaja
Editorial Board: Humma Shahid, Karl Mercieca, Francisco Goni
Editors in Chief: Francesco Oddone, Manuele Michelessi

back to top